Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial

Selina M. Luger, Victoria X. Wang, Jacob M. Rowe, Mark R. Litzow, Elisabeth Paietta, Rhett P. Ketterling, Hillard Lazarus, Witold B. Rybka, Michael D. Craig, Judith Karp, Brenda W. Cooper, Adel Z. Makary, Lynne S. Kaminer, Frederick R. Appelbaum, Richard A. Larson, Martin S. Tallman

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial'. Together they form a unique fingerprint.